For promising clinical benefits may be associated with PD-L1 expression level in early stage treatment, it is pivotal to detecting PD-L1 expression by tumor cell as predictive maker for anti-PD-1/PD-L1 monoclonal antibodies treatment or as prognostic factor for poor survival in NSCLC patients. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.